These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 30353060

  • 1. Checkpoint Inhibitor-Induced Hemorrhagic Gastritis with Pembrolizumab.
    Rao BB, Robertson S, Philpott J.
    Am J Gastroenterol; 2019 Feb; 114(2):196. PubMed ID: 30353060
    [No Abstract] [Full Text] [Related]

  • 2. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Yip RHL, Lee LH, Schaeffer DF, Horst BA, Yang HM.
    Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271
    [Abstract] [Full Text] [Related]

  • 3. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases.
    Jespersen H, Bjursten S, Ny L, Levin M.
    Lancet Oncol; 2018 Jun; 19(6):e327. PubMed ID: 29893264
    [No Abstract] [Full Text] [Related]

  • 4. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
    Earl DE, Loochtan AI, Bedlack RS.
    Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
    [No Abstract] [Full Text] [Related]

  • 5. Pembrolizumab-Induced Alopecia Areata.
    Elshimy N, Blakeway E, Mitra A.
    Skinmed; 2019 Apr; 17(2):142-143. PubMed ID: 31145074
    [No Abstract] [Full Text] [Related]

  • 6. Hypothyroid ataxia complicating monoclonal antibody therapy.
    Badran A, Moran C, Coles AJ.
    Pract Neurol; 2017 Dec; 17(6):482-484. PubMed ID: 28778931
    [Abstract] [Full Text] [Related]

  • 7. Acute localised exanthematous pustulosis secondary to pembrolizumab.
    Wang CY, Khoo C, McCormack CJ, Xu W, Pan Y.
    Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194
    [No Abstract] [Full Text] [Related]

  • 8. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
    Arianayagam S, Ieremia E, Matin RN.
    Eur J Dermatol; 2019 Jun 01; 29(3):349-351. PubMed ID: 31389799
    [No Abstract] [Full Text] [Related]

  • 9. Demyelinating disease of the central nervous system associated with Pembrolizumab treatment for metastatic melanoma.
    Durães J, Coutinho I, Mariano A, Geraldo A, Macário MC.
    Mult Scler; 2019 Jun 01; 25(7):1005-1008. PubMed ID: 30311534
    [Abstract] [Full Text] [Related]

  • 10. PD-1 inhibitor induced alopecia areata.
    Guidry J, Brown M, Medina T.
    Dermatol Online J; 2018 Dec 15; 24(12):. PubMed ID: 30677804
    [Abstract] [Full Text] [Related]

  • 11. Clinical Characteristics and Outcomes of Pembrolizumab Induced Gastritis: A Systematic Review of the Literature.
    Lei H, Sun W, Liu X, Wang C.
    J Gastrointest Cancer; 2024 Sep 15; 55(3):1-8. PubMed ID: 38787493
    [Abstract] [Full Text] [Related]

  • 12. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
    Crusz SM, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, Lim L, Powles T, Szlosarek PW, Shamash J, Rashid S.
    Eur J Cancer; 2018 Oct 15; 102():49-51. PubMed ID: 30138772
    [No Abstract] [Full Text] [Related]

  • 13. Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?
    Kähler KC, Kosova K, Bohne AS, Schreiber S, Hauschild A.
    Eur J Cancer; 2020 Oct 15; 138():169-171. PubMed ID: 32890812
    [No Abstract] [Full Text] [Related]

  • 14. Dual checkpoint inhibitor-associated eosinophilic enteritis.
    Yang J, Lagana SM, Saenger YM, Carvajal RD.
    J Immunother Cancer; 2019 Nov 15; 7(1):310. PubMed ID: 31730503
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma.
    Sanchez A, Montaudie H, Bory P, Belgodere X, Passeron T, Lacour JP, Picard A.
    JAMA Dermatol; 2018 Nov 01; 154(11):1354-1356. PubMed ID: 30326507
    [No Abstract] [Full Text] [Related]

  • 17. Auto-immune gastritis induced by pembrolizumab, an anti-PD-1, in a melanoma patient.
    Vandepapelière J, Siplet J, Libbrecht L, Dano H, Baurain JF, Moreels T.
    Acta Gastroenterol Belg; 2020 Nov 01; 83(3):482-484. PubMed ID: 33094598
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
    Oya K, Nakamura Y, Fujisawa Y, Endo R, Tanaka R, Ishitsuka Y, Maruyama H, Watanabe R, Okiyama N, Fujimoto M.
    Eur J Dermatol; 2018 Feb 01; 28(1):129-130. PubMed ID: 29400284
    [No Abstract] [Full Text] [Related]

  • 20. Generalized morphea in the setting of pembrolizumab.
    Cheng MW, Hisaw LD, Bernet L.
    Int J Dermatol; 2019 Jun 01; 58(6):736-738. PubMed ID: 29931792
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.